| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10046482 | HBV | ENSG00000010671.18 | protein_coding | BTK | Yes | No | 695 | Q06187 Q5JY90 |
| TVIS10057601 | HBV | ENSG00000010671.18 | protein_coding | BTK | Yes | No | 695 | Q06187 Q5JY90 |
| TVIS30021024 | HIV | ENSG00000010671.18 | protein_coding | BTK | Yes | No | 695 | Q06187 Q5JY90 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | BTK |
|---|---|
| DrugBank ID | DB16657 |
| Drug Name | Vecabrutinib |
| Target ID | BE0001284 |
| UniProt ID | Q06187 |
| Regulation Type | inhibitor |
| PubMed IDs | 31028669; 33275726; 31591468 |
| Citations | Bond DA, Woyach JA: Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205. doi: 10.1007/s11899-019-00512-0.@@Castillo JJ, Treon SP: Management of Waldenstrom macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):372-379. doi: 10.1182/hematology.2020000121.@@Castillo JJ, Treon SP: What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 Nov;33(11):2555-2562. doi: 10.1038/s41375-019-0592-8. Epub 2019 Oct 7. |
| Groups | Investigational |
| Direct Classification | |
| SMILES | NC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](NC2=CC(=CC(Cl)=C2)C(F)(F)F)C1=O)C1=NC=NC(N)=C1F |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL4297640 |
